Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aubagio

- PMLiVE

Novartis’ MS therapy Mayzent approved by NICE

Agency approves drug after new cost-effectiveness proposal

- PMLiVE

EU announces agreement with Gilead for remdesivir supply

Drug was granted conditional marketing authorisation in the EU in July

- PMLiVE

J&J signs deal with EU for 200 million COVID-19 vaccine doses

EU member states will have an option to secure 200 million additional doses

- PMLiVE

Sanofi, GSK to launch human trials of COVID-19 vaccine

Vaccine combines Sanofi’s baculovirus expression system and GSK’s AS03 adjuvant

- PMLiVE

Roche’s Ocrevus boasts positive long-term data in MS

After two years of treatment 75% of patients had no evidence of disease activity

EU flag

EU to contribute €400m to WHO’s COVID-19 vaccine facility

Contribution will go towards ensuring equitable access to COVID-19 vaccines

- PMLiVE

EU aims to vaccinate 40% of population in initial COVID-19 blueprint

Target is double the goal set by the World Health Organization

- PMLiVE

COVID-19 vaccine deals with the EU hindered by strict liability rules

Companies would retain liability for unexpected side effects

Sanofi reception

Translate Bio, Sanofi’s COVID-19 vaccine proves promising in animal studies

Vaccine was able to induce neutralising antibodies and T-cell responses

- PMLiVE

EU concludes discussions with Moderna for COVID-19 vaccine

Biotech company on the verge on finalising supply deal

- PMLiVE

Novartis wins FDA approval for relapsing MS drug Kesimpta

Swiss pharma company is expecting EU approval for treatment next year

Sanofi reception

Sanofi bolsters pipeline with $3.7bn deal for Principia Biopharma

French drugmaker will gain access to a portfolio of BTK inhibitors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links